While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares subsequently tumbled more than 50%.
An article from
Dive Brief
While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations.
Published May 7, 2026
By
A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make…
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA…
Zealand and Roche are jointly developing the drug petrelintide which in a mid-stage study led to a worse-than-expected 10.7%…
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA…
Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's…
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its…
